Attorney Docket No.: 5958-US-DIV[2] PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Udagawa et al. Confirmation No: 5785

Serial No.: 10/849,106 Group Art Unit: 1656

Filed: May 19, 2004 Examiner: Nashaat Nashed

For: Lysophospholipase

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This application was filed on May 19, 2004 as a divisional of U.S. Application No. 10/309,437 filed December 4, 2002, which is a divisional of U.S. application no. 09/687,538 filed October 13, 2000, which claims priority or the benefit of Danish application no. PA 1999 01473 filed October 14, 1999 and U.S. provisional application no. 60/160.572 filed October 20, 1999.

The application and the Application Data Sheet submitted by Applicants incorrectly provided that U.S. application no. 09/687,538 is a continuation of U.S. application no. 09/678,513. Thus, the domestic priority data provided in the Filing Receipt mailed October 7, 2004 is incorrect.

Applicants therefore request the issuance of a corrected filing receipt with correct domestic priority data. An Amendment correcting the Cross-Reference to Related Applications section and a Supplemental Application Data Sheet providing the correct domestic priority data are submitted herewith.

All required fees were charged to Novozymes North America, Inc.'s Deposit Account No. 50-1701 at the time of electronic filing. The USPTO is authorized to charge this Deposit Account should any additional fees be due.

Respectfully submitted,

Date: September 20, 2011 /Elias Lambiris, Reg. # 33728/

Elias J. Lambiris, Reg. No. 33,728 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110 (919) 494-3405